Filtered By:
Therapy: Cancer Therapy
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 42071 results found since Jan 2013.
Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma
Cell Mol Life Sci. 2022 Oct 11;79(11):546. doi: 10.1007/s00018-022-04557-y.ABSTRACTThe majority of current cancer therapies are aimed at reducing tumour growth, but there is lack of viable pharmacological options to reduce the formation of metastasis. This is a paradox, since more than 90% of cancer deaths are attributable to metastatic progression. Integrin alpha9 (ITGA9) has been previously described as playing an essential role in metastasis; however, little is known about the mechanism that links this protein to this process, being one of the less studied integrins. We have now deciphered the importance of ITGA9 in met...
Source: Cellular and Molecular Life Sciences : CMLS - October 11, 2022 Category: Cytology Authors: Natalia Navarro Carla Molist J úlia Sansa-Girona Patricia Zarzosa Gabriel Gallo-Oller Guillem Pons Ainara Magdaleno Gabriela Guill én Raquel Hladun Marta Garrido Miguel F Segura Lourdes Hontecillas-Prieto Enrique de Álava Berta Ponsati Jimena Fern ánd Source Type: research
Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review
AbstractRadiotherapy (RT), unlike chemotherapy, is one of the most routinely used and effective genotoxic and immune response inducing cancer therapies with an advantage of reduced side effects. However, cancer can relapse after RT owing to multiple factors, including acquired tumor resistance, immune suppressive microenvironment buildup, increased DNA repair, thus favoring tumor metastasis. Efforts to mitigate these undesirable effects have drawn interest in combining RT with immunotherapy, particularly the use of immune checkpoint inhibitors, to tilt the pre-existing tumor stromal microenvironment into long-lasting thera...
Source: Clinical and Translational Oncology - October 15, 2022 Category: Cancer & Oncology Source Type: research
Single proton LET characterization with the Timepix detector and artificial intelligence for advanced proton therapy treatment planning
Phys Med Biol. 2023 Apr 3. doi: 10.1088/1361-6560/acc9f8. Online ahead of print.ABSTRACTProtons have advantageous dose distributions and are increasingly used in cancer therapy. At the depth of the Bragg peak range, protons produce a mixed radiation field consisting of low- and high-linear energy transfer (LET) components, the latter of which is characterized by an increased ionization density on the microscopic scale associated with increased biological effectiveness. Prediction of the yield and LET of primary and secondary charged particles at a certain depth in the patient is performed by Monte Carlo simulations but is ...
Source: Physics in Medicine and Biology - April 3, 2023 Category: Physics Authors: Paulina Stasica Hanh Nguyen Carlos Granja Renata Kopec Lukas Marek Cristina Oancea Łukasz Raczyński Antoni Rucinski Marzena Rydygier Keith E Schubert Reinhard W Schulte Jan Gajewski Source Type: research
The "Ins and Outs" of Prostate Specific Membrane Antigen (PSMA) as Specific Target in Prostate Cancer Therapy
Adv Exp Med Biol. 2023;1408:291-308. doi: 10.1007/978-3-031-26163-3_16.ABSTRACTProstate-specific membrane antigen (PSMA) is expressed in epithelial cells of the prostate gland and is strongly upregulated in prostatic adenocarcinoma, with elevated expression correlating with metastasis, progression, and androgen independence. Because of its specificity, PSMA is a major target of prostate cancer therapy; however, detectable levels of PSMA are also found in other tissues, especially in salivary glands and kidney, generating bystander damage of these tissues. Antibody target therapy has been used with relative success in reduc...
Source: Advances in Experimental Medicine and Biology - April 24, 2023 Category: Research Authors: Felipe Eltit Nicole Robinson Pak Lok Ivan Yu Mitali Pandey Jerome Lozada Yubin Guo Manju Sharma Dogancan Ozturan Laetitia Ganier Eric Belanger Nathan A Lack David M Perrin Michael E Cox S Larry Goldenberg Source Type: research
